Cargando…
Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
PURPOSE: Genomic testing has increased the quantity of information available to oncologists. Unfortunately, many identified sequence alterations are variants of unknown significance (VUSs), which thus limit the clinician’s ability to use these findings to inform treatment. We applied a combination o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369924/ https://www.ncbi.nlm.nih.gov/pubmed/30761385 http://dx.doi.org/10.1200/PO.17.00018 |
_version_ | 1783394270740217856 |
---|---|
author | Egan, Jan B. Marks, David L. Hogenson, Tara L. Vrabel, Anne M. Sigafoos, Ashley N. Tolosa, Ezequiel J. Carr, Ryan M. Safgren, Stephanie L. Enriquez Hesles, Elisa Almada, Luciana L. Romecin-Duran, Paola A. Iguchi, Eriko Ala’Aldeen, Aryan Kocher, Jean-Pierre A. Oliver, Gavin R. Prodduturi, Naresh Mead, David W. Hossain, Asif Huneke, Norine E. Tagtow, Colleen M. Ailawadhi, Sikander Ansell, Stephen M. Banck, Michaela S. Bryce, Alan H. Carballido, Estrella M. Chanan-Khan, Asher A. Curtis, Kelly K. Resnik, Ernesto Gawryletz, Chelsea D. Go, Ronald S. Halfdanarson, Thorvardur R. Ho, Thai H. Joseph, Richard W. Kapoor, Prashant Mansfield, Aaron S. Meurice, Nathalie Nageswara Rao, Amulya A. Nowakowski, Grzegorz S. Pardanani, Animesh Parikh, Sameer A. Cheville, John C. Feldman, Andrew L. Ramanathan, Ramesh K. Robinson, Steven I. Tibes, Raoul Finnes, Heidi D. McCormick, Jennifer B. McWilliams, Robert R. Jatoi, Aminah Patnaik, Mrinal M. Silva, Alvin C. Wieben, Eric D. McAllister, Tammy M. Rumilla, Kandelaria M. Kerr, Sarah E. Lazaridis, Konstantinos N. Farrugia, Gianrico Stewart, A. Keith Clark, Karl J. Kennedy, Eileen J. Klee, Eric W. Borad, Mitesh J. Fernandez-Zapico, Martin E. |
author_facet | Egan, Jan B. Marks, David L. Hogenson, Tara L. Vrabel, Anne M. Sigafoos, Ashley N. Tolosa, Ezequiel J. Carr, Ryan M. Safgren, Stephanie L. Enriquez Hesles, Elisa Almada, Luciana L. Romecin-Duran, Paola A. Iguchi, Eriko Ala’Aldeen, Aryan Kocher, Jean-Pierre A. Oliver, Gavin R. Prodduturi, Naresh Mead, David W. Hossain, Asif Huneke, Norine E. Tagtow, Colleen M. Ailawadhi, Sikander Ansell, Stephen M. Banck, Michaela S. Bryce, Alan H. Carballido, Estrella M. Chanan-Khan, Asher A. Curtis, Kelly K. Resnik, Ernesto Gawryletz, Chelsea D. Go, Ronald S. Halfdanarson, Thorvardur R. Ho, Thai H. Joseph, Richard W. Kapoor, Prashant Mansfield, Aaron S. Meurice, Nathalie Nageswara Rao, Amulya A. Nowakowski, Grzegorz S. Pardanani, Animesh Parikh, Sameer A. Cheville, John C. Feldman, Andrew L. Ramanathan, Ramesh K. Robinson, Steven I. Tibes, Raoul Finnes, Heidi D. McCormick, Jennifer B. McWilliams, Robert R. Jatoi, Aminah Patnaik, Mrinal M. Silva, Alvin C. Wieben, Eric D. McAllister, Tammy M. Rumilla, Kandelaria M. Kerr, Sarah E. Lazaridis, Konstantinos N. Farrugia, Gianrico Stewart, A. Keith Clark, Karl J. Kennedy, Eileen J. Klee, Eric W. Borad, Mitesh J. Fernandez-Zapico, Martin E. |
author_sort | Egan, Jan B. |
collection | PubMed |
description | PURPOSE: Genomic testing has increased the quantity of information available to oncologists. Unfortunately, many identified sequence alterations are variants of unknown significance (VUSs), which thus limit the clinician’s ability to use these findings to inform treatment. We applied a combination of in silico prediction and molecular modeling tools and laboratory techniques to rapidly define actionable VUSs. MATERIALS AND METHODS: Exome sequencing was conducted on 308 tumors from various origins. Most single nucleotide alterations within gene coding regions were VUSs. These VUSs were filtered to identify a subset of therapeutically targetable genes that were predicted with in silico tools to be altered in function by their variant sequence. A subset of receptor tyrosine kinase VUSs was characterized by laboratory comparison of each VUS versus its wild-type counterpart in terms of expression and signaling activity. RESULTS: The study identified 4,327 point mutations of which 3,833 were VUSs. Filtering for mutations in genes that were therapeutically targetable and predicted to affect protein function reduced these to 522 VUSs of interest, including a large number of kinases. Ten receptor tyrosine kinase VUSs were selected to explore in the laboratory. Of these, seven were found to be functionally altered. Three VUSs (FGFR2 F276C, FGFR4 R78H, and KDR G539R) showed increased basal or ligand-stimulated ERK phosphorylation compared with their wild-type counterparts, which suggests that they support transformation. Treatment of a patient who carried FGFR2 F276C with an FGFR inhibitor resulted in significant and sustained tumor response with clinical benefit. CONCLUSION: The findings demonstrate the feasibility of rapid identification of the biologic relevance of somatic mutations, which thus advances clinicians’ ability to make informed treatment decisions. |
format | Online Article Text |
id | pubmed-6369924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-63699242019-02-11 Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma Egan, Jan B. Marks, David L. Hogenson, Tara L. Vrabel, Anne M. Sigafoos, Ashley N. Tolosa, Ezequiel J. Carr, Ryan M. Safgren, Stephanie L. Enriquez Hesles, Elisa Almada, Luciana L. Romecin-Duran, Paola A. Iguchi, Eriko Ala’Aldeen, Aryan Kocher, Jean-Pierre A. Oliver, Gavin R. Prodduturi, Naresh Mead, David W. Hossain, Asif Huneke, Norine E. Tagtow, Colleen M. Ailawadhi, Sikander Ansell, Stephen M. Banck, Michaela S. Bryce, Alan H. Carballido, Estrella M. Chanan-Khan, Asher A. Curtis, Kelly K. Resnik, Ernesto Gawryletz, Chelsea D. Go, Ronald S. Halfdanarson, Thorvardur R. Ho, Thai H. Joseph, Richard W. Kapoor, Prashant Mansfield, Aaron S. Meurice, Nathalie Nageswara Rao, Amulya A. Nowakowski, Grzegorz S. Pardanani, Animesh Parikh, Sameer A. Cheville, John C. Feldman, Andrew L. Ramanathan, Ramesh K. Robinson, Steven I. Tibes, Raoul Finnes, Heidi D. McCormick, Jennifer B. McWilliams, Robert R. Jatoi, Aminah Patnaik, Mrinal M. Silva, Alvin C. Wieben, Eric D. McAllister, Tammy M. Rumilla, Kandelaria M. Kerr, Sarah E. Lazaridis, Konstantinos N. Farrugia, Gianrico Stewart, A. Keith Clark, Karl J. Kennedy, Eileen J. Klee, Eric W. Borad, Mitesh J. Fernandez-Zapico, Martin E. JCO Precis Oncol Original Reports PURPOSE: Genomic testing has increased the quantity of information available to oncologists. Unfortunately, many identified sequence alterations are variants of unknown significance (VUSs), which thus limit the clinician’s ability to use these findings to inform treatment. We applied a combination of in silico prediction and molecular modeling tools and laboratory techniques to rapidly define actionable VUSs. MATERIALS AND METHODS: Exome sequencing was conducted on 308 tumors from various origins. Most single nucleotide alterations within gene coding regions were VUSs. These VUSs were filtered to identify a subset of therapeutically targetable genes that were predicted with in silico tools to be altered in function by their variant sequence. A subset of receptor tyrosine kinase VUSs was characterized by laboratory comparison of each VUS versus its wild-type counterpart in terms of expression and signaling activity. RESULTS: The study identified 4,327 point mutations of which 3,833 were VUSs. Filtering for mutations in genes that were therapeutically targetable and predicted to affect protein function reduced these to 522 VUSs of interest, including a large number of kinases. Ten receptor tyrosine kinase VUSs were selected to explore in the laboratory. Of these, seven were found to be functionally altered. Three VUSs (FGFR2 F276C, FGFR4 R78H, and KDR G539R) showed increased basal or ligand-stimulated ERK phosphorylation compared with their wild-type counterparts, which suggests that they support transformation. Treatment of a patient who carried FGFR2 F276C with an FGFR inhibitor resulted in significant and sustained tumor response with clinical benefit. CONCLUSION: The findings demonstrate the feasibility of rapid identification of the biologic relevance of somatic mutations, which thus advances clinicians’ ability to make informed treatment decisions. American Society of Clinical Oncology 2017-08-01 /pmc/articles/PMC6369924/ /pubmed/30761385 http://dx.doi.org/10.1200/PO.17.00018 Text en © 2017 by American Society of Clinical Oncology http://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Reports Egan, Jan B. Marks, David L. Hogenson, Tara L. Vrabel, Anne M. Sigafoos, Ashley N. Tolosa, Ezequiel J. Carr, Ryan M. Safgren, Stephanie L. Enriquez Hesles, Elisa Almada, Luciana L. Romecin-Duran, Paola A. Iguchi, Eriko Ala’Aldeen, Aryan Kocher, Jean-Pierre A. Oliver, Gavin R. Prodduturi, Naresh Mead, David W. Hossain, Asif Huneke, Norine E. Tagtow, Colleen M. Ailawadhi, Sikander Ansell, Stephen M. Banck, Michaela S. Bryce, Alan H. Carballido, Estrella M. Chanan-Khan, Asher A. Curtis, Kelly K. Resnik, Ernesto Gawryletz, Chelsea D. Go, Ronald S. Halfdanarson, Thorvardur R. Ho, Thai H. Joseph, Richard W. Kapoor, Prashant Mansfield, Aaron S. Meurice, Nathalie Nageswara Rao, Amulya A. Nowakowski, Grzegorz S. Pardanani, Animesh Parikh, Sameer A. Cheville, John C. Feldman, Andrew L. Ramanathan, Ramesh K. Robinson, Steven I. Tibes, Raoul Finnes, Heidi D. McCormick, Jennifer B. McWilliams, Robert R. Jatoi, Aminah Patnaik, Mrinal M. Silva, Alvin C. Wieben, Eric D. McAllister, Tammy M. Rumilla, Kandelaria M. Kerr, Sarah E. Lazaridis, Konstantinos N. Farrugia, Gianrico Stewart, A. Keith Clark, Karl J. Kennedy, Eileen J. Klee, Eric W. Borad, Mitesh J. Fernandez-Zapico, Martin E. Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma |
title | Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma |
title_full | Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma |
title_fullStr | Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma |
title_full_unstemmed | Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma |
title_short | Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma |
title_sort | molecular modeling and functional analysis of exome sequencing–derived variants of unknown significance identify a novel, constitutively active fgfr2 mutant in cholangiocarcinoma |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369924/ https://www.ncbi.nlm.nih.gov/pubmed/30761385 http://dx.doi.org/10.1200/PO.17.00018 |
work_keys_str_mv | AT eganjanb molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT marksdavidl molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT hogensontaral molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT vrabelannem molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT sigafoosashleyn molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT tolosaezequielj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT carrryanm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT safgrenstephaniel molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT enriquezhesleselisa molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT almadalucianal molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT romecinduranpaolaa molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT iguchieriko molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT alaaldeenaryan molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT kocherjeanpierrea molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT olivergavinr molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT prodduturinaresh molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT meaddavidw molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT hossainasif molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT hunekenorinee molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT tagtowcolleenm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT ailawadhisikander molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT ansellstephenm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT banckmichaelas molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT brycealanh molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT carballidoestrellam molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT chanankhanashera molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT curtiskellyk molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT resnikernesto molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT gawryletzchelsead molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT goronalds molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT halfdanarsonthorvardurr molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT hothaih molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT josephrichardw molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT kapoorprashant molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT mansfieldaarons molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT meuricenathalie molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT nageswararaoamulyaa molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT nowakowskigrzegorzs molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT pardananianimesh molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT parikhsameera molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT chevillejohnc molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT feldmanandrewl molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT ramanathanrameshk molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT robinsonsteveni molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT tibesraoul molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT finnesheidid molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT mccormickjenniferb molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT mcwilliamsrobertr molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT jatoiaminah molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT patnaikmrinalm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT silvaalvinc molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT wiebenericd molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT mcallistertammym molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT rumillakandelariam molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT kerrsarahe molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT lazaridiskonstantinosn molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT farrugiagianrico molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT stewartakeith molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT clarkkarlj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT kennedyeileenj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT kleeericw molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT boradmiteshj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma AT fernandezzapicomartine molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma |